

Ref: MHL/Sec&Legal/2026-27/11

May 13, 2026

To,
BSE Limited
Scrip Code: 542650

National Stock Exchange of India Ltd.
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is the Press Release as mentioned below:

“Metropolis Healthcare reports strong Q4FY26 performance; EBITDA up 71% YoY and PAT rises 75% YoY.”

You are requested to take the above information on record.

Thanking you,
Yours faithfully,

For **Metropolis Healthcare Limited**

Kamlesh C Kulkarni
Head – Legal & Secretarial

Encl: A/a



PRESS RELEASE


Metropolis Healthcare reports strong Q4FY26 performance; EBITDA up 71% YoY and PAT rises 75% YoY.

~ **Robust demand and operational efficiencies** drive margin expansion and profitability improvement ~

~ **Crosses 5,000+ centres milestone**; strengthening accessibility and market presence across India~

~ The Board has approved a dividend of **₹1 per share**.

Mumbai, India, 13th May 2026: Ameera Shah-led Metropolis Healthcare Limited (**NSE: METROPOLIS | BSE: 542650**), India’s second-largest and the most respected pathology laboratory chain, today announced its unaudited consolidated financial results for the quarter ended March 31st, 2026.



Q4FY26 – Financial & Operational Highlights

- **Patient volumes grew 11% YoY, and test volumes increased 14% YoY**, reflecting sustained demand momentum, deeper market penetration and stronger clinician engagement.
- **B2C revenues grew 20% YoY**, driven by rising adoption of preventive and specialized testing, stronger digital engagement and hyperlocal marketing initiatives.
- **B2B revenues increased 28% YoY**, aided by strong client retention, hospital outsourcing opportunities, deeper partner relationships and improved service reliability.
- **TruHealth and Specialty portfolios grew 24% YoY and 31% YoY respectively, reflecting** increasing consumer preference for preventive healthcare and advanced & high-end diagnostics.
- **Revenue per Patient (RPP) improved 11% YoY, while Revenue per Test (RPT) increased 8% YoY**, supported by favourable mix and higher contribution from specialised testing.

“The diagnostics industry in India is evolving towards more organised and science-led platforms, driven by increasing focus on trust, accuracy and clinical excellence. At Metropolis, our focus on scientific excellence, strong doctor relationships and advanced diagnostics positions us well in this evolving healthcare landscape. In Q4FY26, Metropolis delivered robust growth, with revenue increasing 23% YoY, while expanding our network beyond 5,000 centres across India. With healthcare increasingly moving towards preventive and personalised care, we remain committed to building a differentiated diagnostics platform driven by quality, innovation and customer trust.” ~ **Ms. Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited**

“FY26 was an important year from an execution and operating transformation standpoint for Metropolis. Growth during the year was driven by healthy patient volumes, improved mix and stronger realisations, without any price increase in Q4, reflecting the strength of the underlying demand environment. We also made steady progress in productivity, network utilisation, lab optimisation and acquisition integration, supporting operating leverage and meaningful margin expansion. Going forward, we remain focused on driving sustainable growth, improving network throughput and delivering further efficiency-led margin expansion over the medium term.” ~ **Mr. Surendran Chemmenkotil, Managing Director, Metropolis Healthcare Limited**

Financial Results Snapshot – Q4FY26

In INR Crs.	Q4FY25	Q4FY26 (MHL Organic)	Y-o-Y	Q4FY26 (MHL Group)	Y-o-Y
Revenue from Operations	341.7	392.1	14.7%	424.7	23.0%
Adj EBITDA	84	106.6	26.9%	108.0	28.5%
One-Time Expenses	21.0	0.0		0.0	
Reported EBITDA	63.0	106.6	69.1%	108.0	71.3%
Reported EBITDA Margin (%)	18.5%	27.2%		25.4%	
Profit After Tax	29.2	55.2	88.9%	51.0	74.5%
PAT Margin (%)	8.6%	14.1%		12.0%	

Financial Results Snapshot – FY26

In INR Crs.	FY25	FY26 (MHL Organic)	Y-o-Y	FY26 (MHL Group)	Y-o-Y
Revenue from Operations	1,327.6	1,509.6	13.7%	1,645.8	23.6%
Adj EBITDA	325.3	391.6	20.4%	400.8	23.2%
One-Time Expenses	21.0	0.0		0.0	
Reported EBITDA	304.3	391.6	28.7%	400.8	31.7%
Reported EBITDA Margin (%)	22.9%	25.9%		24.4%	
Profit After Tax	145.5	193.8	33.2%	191.2	31.4%
PAT Margin (%)	11.0%	12.8%		11.6%	

About Metropolis Healthcare Limited: Established in 1981, Metropolis Healthcare Limited is India’s second-largest diagnostic chain, led by visionary leader Ms. Ameera Shah. With over four decades of excellence, Metropolis has been a pioneer in delivering best-in-class diagnostic services to patients, healthcare providers, and corporates across India and Africa. The company’s extensive footprint spans 28 states, 7 Union Territories, and over 750+ towns in India, supported by a robust network of more than 221 laboratories, ~ 5000 plus patient service centers, and over 10,000 touchpoints. Each year, Metropolis serves millions of individuals by providing actionable health insights that empower better clinical outcomes.

Metropolis offers a comprehensive range of more than 4,100 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company’s commitment to quality and accuracy is reinforced by its consistent CAP proficiency score of over 99% for the past decade, placing it among the top 1% of laboratories worldwide for quality assurance. The Metropolis philosophy is

built on the pillars of technological superiority, a warm, patient-centric approach, and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#)

Safe harbor statement: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

<p>Company: Metropolis Healthcare Ltd.</p> <p>CIN: L73100MH2000PLC192798 Mr. Jeyasingh Balakrishnan Head – Corporate Communications & CSR +91 9833836185 Email: jeyasingh.b@metropolisindia.com</p>	<p>Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd.</p> <p>CIN: U74140MH2010PTC204285 Mr. Shogun Jain / Mr. Sagar Shroff +91 77383 77756 / +91 98205 19303 Email: shogun.jain@sgapl.net / sagar.shroff@sgapl.net</p>
---	--